<DOC>
	<DOCNO>NCT01145638</DOCNO>
	<brief_summary>The purpose study compare efficacy safety intravenous iron therapy oral iron therapy patient cancer chemotherapy induce anaemia .</brief_summary>
	<brief_title>A Study Intravenous Iron Isomaltoside 1000 ( MonoferÂ® ) Mono Therapy ( Without Erythropoiesis Stimulating Agents ) Comparison With Oral Iron Sulfate Subjects With Non-myeloid Malignancies Associated With Chemotherapy Induced Anaemia ( CIA )</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>1 . Men woman , age 18 year . 2 . Subjects diagnose cancer ( nonmyeloid malignancy ) receive chemotherapy least 1 day prior screen go receive least two chemotherapy cycle . 3 . Hb &lt; 12 g/dL ( 7.4 mmol/L ) . 4 . TfS &lt; 50 % . 5 . Serum Ferritin &lt; 800 ng/ml . 6 . An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 7 . Willingness participate inform consent ( include HIPAA , applicable ) . 1 . Anemia cause primarily factor CIA . 2 . IV oral iron treatment within 4 week prior screen visit . 3 . Erythropoietin treatment within 4 week prior screen visit . 4 . Blood transfusion within 4 week prior screen visit . 5 . Imminent expectation blood transfusion part treat physician . 6 . Iron overload disturbance utilization iron ( e.g . haemochromatosis haemosiderosis ) . 7 . Drug hypersensitivity ( i.e . previous hypersensitivity Iron Dextran iron mono disaccharide complex iron sulfate ) . 8 . Known hypersensitivity excipients investigational drug product . 9 . Subjects history multiple allergy . 10 . Decompensated liver cirrhosis active hepatitis ( alanine aminotransferase ( ALAT ) &gt; 3 time upper normal limit ) . 11 . Active acute chronic infection ( assessed clinical judgement deem necessary investigator supply white blood cell ( WBC ) Creactive protein ( CRP ) ) . 12 . Rheumatoid arthritis symptom sign active joint inflammation . 13 . Pregnancy nursing ( To avoid pregnancy , woman postmenopausal ( least 12 month must elapse since last menstruation ) , surgically sterile , woman child bear potential must use one follow contraceptive whole study period study end least 5 time plasma biological halflife investigational medicinal product : Contraceptive pill , intrauterine device ( IUD ) , contraceptive depot injection ( prolongedrelease gestagen ) , subdermal implantation , vaginal ring , transdermal patch ) . 14 . Planned elective surgery study . 15 . Participation clinical study ( except chemotherapy protocol ) within 3 month prior screen . 16 . Known intolerance oral iron treatment . 17 . Untreated B12 folate deficiency . 18 . Any medical condition , opinion Principal Investigator , may cause subject unsuitable completion study place subject potential risk study . Example , Uncontrolled Hypertension , Unstable Ischemic Heart Disease Uncontrolled Diabetes Mellitus .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>cancer</keyword>
	<keyword>chemotherapy induce anaemia</keyword>
	<keyword>iron</keyword>
	<keyword>Patients non-myeloid malignancy Chemotherapy Induced Anaemia ( CIA )</keyword>
	<keyword>CIA</keyword>
</DOC>